CN102154405A - Preparation method of hyaluronic acid - Google Patents
Preparation method of hyaluronic acid Download PDFInfo
- Publication number
- CN102154405A CN102154405A CN2011100062269A CN201110006226A CN102154405A CN 102154405 A CN102154405 A CN 102154405A CN 2011100062269 A CN2011100062269 A CN 2011100062269A CN 201110006226 A CN201110006226 A CN 201110006226A CN 102154405 A CN102154405 A CN 102154405A
- Authority
- CN
- China
- Prior art keywords
- hyaluronic
- hyaluronic acid
- phk
- synthetic
- fermentation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 108
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 105
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 105
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 241000894006 Bacteria Species 0.000 claims description 34
- 238000000855 fermentation Methods 0.000 claims description 28
- 230000004151 fermentation Effects 0.000 claims description 28
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 23
- 210000001072 colon Anatomy 0.000 claims description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 17
- 239000008103 glucose Substances 0.000 claims description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 13
- 239000004254 Ammonium phosphate Substances 0.000 claims description 12
- 229910000148 ammonium phosphate Inorganic materials 0.000 claims description 12
- 235000019289 ammonium phosphates Nutrition 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- 230000001186 cumulative effect Effects 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 8
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 239000007789 gas Substances 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- XQSPNYNSJBNQHQ-DBKUKYHUSA-N C(C)(=O)C1(O)[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO.[N] Chemical compound C(C)(=O)C1(O)[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO.[N] XQSPNYNSJBNQHQ-DBKUKYHUSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- 238000012807 shake-flask culturing Methods 0.000 claims description 4
- 210000001082 somatic cell Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 21
- 238000000034 method Methods 0.000 abstract description 18
- 239000013604 expression vector Substances 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 11
- 108700005078 Synthetic Genes Proteins 0.000 abstract description 5
- 108010054269 Uridine Diphosphate Glucose Dehydrogenase Proteins 0.000 abstract description 2
- 238000003259 recombinant expression Methods 0.000 abstract 2
- 241001478240 Coccus Species 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 23
- 101710088194 Dehydrogenase Proteins 0.000 description 20
- 230000000968 intestinal effect Effects 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 19
- 241000588724 Escherichia coli Species 0.000 description 16
- HSCJRCZFDFQWRP-RDKQLNKOSA-N UDP-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-RDKQLNKOSA-N 0.000 description 14
- 230000001580 bacterial effect Effects 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 101150105185 kfiD gene Proteins 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 241000606856 Pasteurella multocida Species 0.000 description 8
- 229940051027 pasteurella multocida Drugs 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- 102000018866 Hyaluronan Receptors Human genes 0.000 description 7
- 108010013214 Hyaluronan Receptors Proteins 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000012138 yeast extract Substances 0.000 description 6
- MVMSCBBUIHUTGJ-LRJDVEEWSA-N GDP-alpha-D-glucose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=C(NC(=O)C=2N=C1)N)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O MVMSCBBUIHUTGJ-LRJDVEEWSA-N 0.000 description 5
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 5
- 241000178955 Pasteurella multocida subsp. multocida Species 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 4
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 229940097043 glucuronic acid Drugs 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- XUWPJKDMEZSVTP-LTYMHZPRSA-N kalafungina Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1[C@@H](C)O[C@H]1[C@@H]2OC(=O)C1 XUWPJKDMEZSVTP-LTYMHZPRSA-N 0.000 description 3
- 238000011031 large-scale manufacturing process Methods 0.000 description 3
- 238000012269 metabolic engineering Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 239000012137 tryptone Substances 0.000 description 3
- KCOYLRXCNKJSSC-UHFFFAOYSA-N 9h-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1.C1=CC=C2C3=CC=CC=C3NC2=C1 KCOYLRXCNKJSSC-UHFFFAOYSA-N 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 206010018325 Congenital glaucomas Diseases 0.000 description 2
- 101150097493 D gene Proteins 0.000 description 2
- 206010012565 Developmental glaucoma Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- QGWNDRXFNXRZMB-UUOKFMHZSA-K GDP(3-) Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-K 0.000 description 2
- 101710128038 Hyaluronan synthase Proteins 0.000 description 2
- 208000007157 Hydrophthalmos Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000701245 Paramecium bursaria Chlorella virus 1 Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 241001655322 Streptomycetales Species 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 201000001024 buphthalmos Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 230000029052 metamorphosis Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000010414 supernatant solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108010046845 tryptones Proteins 0.000 description 2
- KIUKXJAPPMFGSW-YXBJCWEESA-N (2s,4s,5r,6s)-6-[(2s,3r,5s,6r)-3-acetamido-2-[(3s,4r,5r,6r)-6-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@@H]3[C@@H]([C@@H](O)C(O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)C(C(O)=O)O1 KIUKXJAPPMFGSW-YXBJCWEESA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 101500000959 Bacillus anthracis Protective antigen PA-20 Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000561734 Celosia cristata Species 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000223785 Paramecium Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 102000057144 Uridine Diphosphate Glucose Dehydrogenase Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001716 carbazoles Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- -1 methane amide Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N n-(3,4,5,6-tetrahydroxy-1-oxohexan-2-yl)acetamide Chemical compound CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000000710 polymer precipitation Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010010 raising Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940035658 visco-gel Drugs 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Abstract
The invention provides a preparation method of hyaluronic acid. The method comprises the following steps: transforming a recombinant expression vector into the colibacillus to obtain engineering colibacillus by constructing the recombinant expression vector of which hyaluronic acid synzyme gene Has and uridine diphosphate glucose dehydrogenase gene are jointly expressed in the colibacillus; and fermenting the engineering colibacillus to obtain the hyaluronic acid. After the method is used, the production yield of the hyaluronic acid achieves 2.5g/L. compared with the prior art, the yield of the highest HA (hyaluronic acid) obtained by gram positive chained coccus HA synthetic gene spHas expressed in the colibacillus is approximately improved by 10 times.
Description
Technical field
The present invention relates to the gene engineering technology field of microorganism, specifically is to produce hyaluronic preparation method with the plasmid form or with the engineering colon bacillus that the genome conformity mode makes up.
Background technology
E. coli k12 strain system because of genetic background clearly, have numerous genetic transformation systems efficiently and genomic ease for operation is widely used in the metabolic engineering field, to produce high value added product miscellaneous.Do not find as yet at present that natural coli strain has the hyaluronic ability of production.
(Hyaluronic acid HA) separates obtain a kind of and has the high viscosity glycosaminoglycan hyaluronic acid the earliest from buphthalmos.Hyaluronic acid extensively exists in the humans and animals tissue, and its molecular weight is 5 * 10
4To 8 * 10
6Between the dalton, be by β-1, glucuronic acid and β-1 that the 4-glycosidic link connects; nitrogen ethanoyl glucosamine (the β 1-4 D-Glucuronic acid that the 3-glycosidic link connects; GlcA, β 1-3 D-N-acetylglucosamine, the straight-chain polymer that GlcNAc) alternately is formed by connecting.Studies confirm that this polysaccharide has participated in numerous physiological activities such as mammiferous fertilization, fetal development, revascularization and joint lubrication as structure and signaling molecule; Also playing an important role aspect inflammation and injury repairing, the moisture of keeping skin and the elasticity simultaneously.
Discover that the HA oligonucleotide chain of length-specific is being brought into play important function at aspects such as the unusual reparations of antineoplastic immune.Because hyaluronic acid unique chemical characteristic and physiological function, HA and the oligonucleotide chain that comes from HA are widely used in all many-sides such as ophthalmologic operation, arthritis treatment, antitumor, administering mode, cosmetic industry, only HA in 2008 is as raw material, and the dealing money in the world market is about 1,000,000,000 dollars and the trend that increases is year by year arranged.
Occurring in nature HA extensively exists, as the cell envelope of animal tissues Mammals cause of disease bacterium and the chlorella of viral PBCV-1 dip-dye etc.Present commercial HA mainly from the pathogenic bacteria of animal tissues's (as cockscomb, umbilical cord, buphthalmos, knuckle synovia) and cultivator and higher mammal (as strep,
Streptococci) the middle extraction.For the consideration of aspects such as resource limit, cost problem and safety of medicine, above-mentioned production is ideal style absolutely not, and the method for more economic, safe and lasting production HA is done one's utmost to explore by international community.
Molecular biology and development of biology are for the solution of the problems referred to above provides important means.To HA synthesis mechanism in animal and microorganism, the researchs such as clone of the building-up process indispensable gene of many HA all are the means by metabolic engineering, and reconstruction or transformation route of synthesis are produced HA and established solid basis in the host living beings of safety.
Japanese scholar in 2004
Chai paddy grows youth etc.(Chinese patent application number be 200480022328.8) attempts HA synthesizing in plant tissue by express the HA synthetic gene (Has) that obtains from human and paramecium virus (PBCV-1) in transgenic plant.Widner B etc. (Bill Widner et al., Hyaluronic Acid Production in
Bacillus subtilis Appl. Environ. Microbiol. 2005,71 (7): 3747 – 3752) successful expression obtains from gram-positive strep in subtilis HA synthetic gene, the engineering genus bacillus is fermented in common triangular flask and obtains 0.5-0.6g/L HA content.
Yet produce hyaluronic acid in plant, because of the conversion difficulty of plant, growth cycle is subject to seasonal restrictions, and many conservative environmentalists oppose transgenic plant, and there is environmentally safe potential hazard etc. in transgenic plant itself and is subjected to application limitations.For subtilis, because of this bacterium has the generation intracellular toxin, the report of various big ring grease classes and lipopeptide antibiotic, and can cause through fermentation, be used for the separation and purification cost up of field of medicaments HA, serial problems such as productive rate reduction.
Many intestinal bacteria that derive from human intestinal are beneficial bacterias of safeguarding intestinal microbial balance and HUMAN HEALTH.In addition e. coli k12 strain cording clearly genetic background, have numerous genetic transformation systems efficiently and genome operability, and be widely used in the biological product of metabolic engineering field with the production high added value.For being that the host carries out the Stephanopoulos G study group that the hyaluronic reported first of engineered production is a Massachusetts Institute Technology with intestinal bacteria.2008 these study group pass through at expression in escherichia coli Gram-positive strep HA synthetic gene
SpHasWith brand-new synthetic, optimized codon and be used for escherichia coli expression
SeHasGene, this research obtain the HA output of the highest about 0.2g/L.This project intestinal bacteria are difficult to obtain the industrialization utilization because of the HA synthetic yield is low.
Summary of the invention
The purpose of this invention is to provide a kind of hyaluronic preparation method who produces with efficient product hyaluronic acid engineering colon bacillus.Overcome and produce hyaluronic shortage of resources, safety issue and low hyaluronic acid synthetic problem in engineering colon bacillus in the prior art.
The present invention produces hyaluronic acid with the efficient product hyaluronic acid engineering colon bacillus of a kind of expression hyaluronan synthase gene (hyaluronic acid synthase Has) and uridine diphosphoglucose dehydrogenase gene (UDP-glucose Dehydrogenase).
The efficient product hyaluronic acid engineering colon bacillus that contains hyaluronan synthase gene and uridine diphosphoglucose dehydrogenase gene is to make up acquisition by the following method:
(1) carrier of construction expression hyaluronan synthase gene Has specifically is that the Has that PCR clones is connected in the colibacillary expression vector (as pQE80l);
(2) carrier of construction expression uridine diphosphoglucose dehydrogenase gene, the uridine diphosphoglucose dehydrogenase gene that PCR is cloned connects in the colibacillary expression vector (as pQE80l);
(3) structure contains hyaluronan synthase gene Has
,With contain the uridine diphosphoglucose dehydrogenase gene, the recombinant vectors of co expression in intestinal bacteria; The uridine diphosphoglucose dehydrogenase gene expression carrier that contains with structure in (2) is the template of PCR, and amplification contains driven element (as T5) and drives
KfiThe PCR product that D expresses, and be connected into the expression hyaluronan synthase gene that makes up in (1)
HasExpression vector in and obtain to contain hyaluronan synthase gene
HasWith the uridine diphosphoglucose dehydrogenase gene, and can be in intestinal bacteria the recombinant vectors of co expression.
(4) hyaluronan synthase gene will be obtained to contain in (3)
HasWith the recombinant vectors of uridine diphosphoglucose dehydrogenase gene, transformed into escherichia coli (as the JM109 bacterial strain) obtains the hyaluronic engineering colon bacillus of efficient product through screening.
The hyaluronic engineering colon bacillus of efficient product that contains hyaluronan synthase gene Has and uridine diphosphoglucose dehydrogenase gene used among the present invention is pHK/JM109, classification called after colon bacillus (
Escherichia coli), preserving number is CGMCC No.3926, China Committee for Culture Collection of Microorganisms common micro-organisms center (the being called for short CGMCC) preservation on June 17th, 2010 in the BeiJing, China city.
Hyaluronan synthase gene described in the hyaluronic engineering colon bacillus CGMCC of the described efficient product NO:3926
HasDerive from Pasteurella multocida (
Pasteurella multocida subsp. Multocida) in hyaluronan synthase gene
PmHasDescribed uridine diphosphoglucose dehydrogenase gene derives from GDPG dehydrogenase gene in the intestinal bacteria k5 bacterial strain
KfiDDescribed expression vector host strain, e. coli jm109 are purchased the company in Promega.
By coexpression hyaluronan synthase gene and contain the engineering colon bacillus pHK/JM109 of uridine diphosphoglucose dehydrogenase gene, and make it utilize simple carbohydrate (as glucose) to synthesize hyaluronic acid.
Produce hyaluronic output for further improving engineering colon bacillus of the present invention,, add fermentation substrate such as nitrogen acetyl grape amine, citric acid in the substratum and make hyaluronic output obtain a large amount of raisings by changing the aeration condition of fermentation culture.
It is as follows to produce hyaluronic method with engineering colon bacillus pHK/JM109:
(1) shake-flask culture is synthetic
Shake-flask culture is synthetic:
In the 500ml triangular flask, contain 25-50 mM K with cumulative volume 100ml-500ml
2HPO
43H
2O, pH6.5-7.2,2-4mM g/L MgSO47H2O, 20-40 mM/L citric acid, 1-2 mM MnCl
2, 300-400 mM glucose 50-75 mM nitrogen acetylglucosamine adds in the system of 5-10 mM lactose, 10-30 g/L glycerine, 3-5g/L Casamino acid (caseinic acid hydrolyzate) and expresses
PmHasWith
KfiThe pHK/JM109 of D makes somatic cells concentration reach 4-5%(W/V), fermentation condition is 30-33 ℃, 250 rpm, and as follows with 28% V/V() ammoniacal liquor regulate pH to neutral, the fermentation reaction time is 30-36 hour.
HA content can reach (Fig. 1) about 0.75-1 g/L after measured.Because of the synthetic aerobic of HA and than stable p H, for further improving the output of engineering bacteria, the present invention has carried out fermentor tank HA synthetic and has cultivated.
(2) fermentor cultivation is synthetic:
Receive mycin from (penbritin) Amp50-100ug/ml+Km(card) the LB flat board of 25-100ug/ml provokes 3-5 through the single bacterium colony of the pHK/JM109 of line and incubated overnight, place 100ml TB substratum (Terrific Broth:12 g/L peptone (Tryptone), 24 g/L yeast extracts (Yeast extract), 9.4 g/L K
2HPO
4With 2.2 g/L KH
2PO
4, pH6.8) incubated overnight; This culture is through centrifugal collection thalline, thalline suspends with 20-50ml TB, all change the fermentor tank of 1-5L over to, fermentation tank culture medium is the TB substratum and contains Amp50-100 ug/ml+Kmn25-100 ug/ml, cumulative volume is 600-3000 ml, 37 ℃ of controlled temperature, rotating speed 1200 rpm, feeding flow is the mixed gas (oxygen: air 1:10 v/v) of 60 ml/min, be oxygen: air 1:10 v/v, and, cultivated 4 hours, as culture OD with 8% V/V ammoniacal liquor and 4 mol/L HCl adjusting pH to 6.8-7.2
600Reach at 5 o'clock, adding IPTG makes its final concentration reach 0.5-1 mM, simultaneously temperature of reaction being adjusted to 30-33 ℃ cultivated 2 hours, add 50% W/V glucose and 10% W/V ammonium phosphate pH6.8 this moment, make that glucose and ammonium phosphate content are respectively 50 g/L and 1 g/L in the fermented liquid, cultivate after 10 hours for 30 ℃, adding IPTG, glucose and ammonium phosphate once more makes its concentration be respectively 0.5 mM, 50 g/L and 1 g/L, mixed solution is cultivated after 14-30 hour for 30 ℃ and is finished fermentation, obtains the hyaluronic acid of 2-2.5 g/L concentration.
Carry out the production of HA in fermentor tank, cell concn is greatly improved, OD
600Can reach 25-30, HA content obtains 2-3g/L, has improved synthesis capability greatly, for the condition (see figure 1) has been prepared in large-scale production.
Compared with prior art, the invention has the beneficial effects as follows:
1, engineering colon bacillus of the present invention can produce hyaluronic acid 2g/L~2.5g/L, than in the prior art by expression in escherichia coli Gram-positive strep HA synthetic gene spHas and brand-new synthetic, the hyaluronic acid volume of production of the highest about 0.2g/L that optimized codon and be used for that the seHas gene of escherichia coli expression obtains improves nearly 10 times.)
2, the present invention is used in the hyaluronan synthase gene pmHas of derived from gram-negative bacteria for the first time and contains the uridine diphosphoglucose dehydrogenase gene
KfiD expresses in the Gram-negative host and produces hyaluronic acid.
Description of drawings
Fig. 1 is the metamorphosis figure behind the synthetic hyaluronic acid of efficient product hyaluronic acid intestinal bacteria pHK/JM109 of the present invention, wherein: A, C:pQE80l/JM109(control strain) use the observation of simple microscope and environmental scanning electronic microscope (ESEM) respectively; B, D:pHK/JM109 use the observation of simple microscope and environmental scanning electronic microscope (ESEM) respectively; A among the B, b, c, d: after the matter that shows transparency acid was synthetic, it is big that thalline becomes, the situation of mutual sticking connection between two bacterium individualities.
Fig. 2 is of the present invention by HA cumulative change figure in the triangular flask cultivation and fermentation process; Show among the figure that pHK/JM109 produces the hyaluronic acid ability greater than pQHK/JM109, and the empty carrier bacterial strain there is not hyaluronic generation.
Fig. 3 is the Fu Jitu of hyaluronic acid (HA) in supernatant in the bacterial strain pHK/JM109 fermentation purge process of the present invention, A:pHK/JM109, and B: the no hyaluronic acid of contrast (pQE80l/JM109) generates.
Fig. 4 produces best hyaluronic acid engineering strain pHK/JM109 through shake flask fermentation among the present invention, the consumption variation diagram of cell concn, hyaluronic accumulation and substrate after fermentation cylinder for fermentation.Showed cell concentration is greatly improved among the figure, OD
600Can reach 25-30, HA content obtains 2-2.5g/L, has put forward synthesis capability greatly, for condition has been prepared in large-scale production.
Embodiment
Embodiment 1
Hyaluronic shake-flask culture is synthetic among the pHK/JM109:
In the 500ml triangular flask, contain 50 mM K with cumulative volume 100ml
2HPO
43H
2O, (pH7.0) 4mM g/L MgSO47H2O, the 20mM/L citric acid, 1mM MnCl2,300mM glucose 50 mM nitrogen acetylglucosamines (GlcNAc), 10mM lactose, 10g/L glycerine, 5g/LCasamino acid(casamino acids) system in add and express
PmHasWith
KfiThe pHK/JM109 of D makes somatic cells concentration reach 5%(W/V), fermentation condition is 30 ℃, 250rpm, and use 28%(V/V) ammoniacal liquor regulate pH to neutral, the fermentation reaction time is 36 hours.HA content can reach 0.75-1 g/L left and right sides (see figure 2) after measured.
Embodiment 2
In the 2500l triangular flask, contain 25 mM K with cumulative volume 500ml
2HPO
43H
2O, (pH6.5) 2mM g/L MgSO47H2O, 40mM/L citric acid, 2mM MnCl2,400mM glucose 75 mM nitrogen acetylglucosamines (GlcNAc) add in the system of 5mM lactose, 30g/L glycerine, 3g/L casamino acids (Casamino acid) and express
PmHasWith
KfiThe pHK/JM109 of D makes somatic cells concentration reach 4%(W/V), fermentation condition is 33 ℃, 250rpm, and use 28%(V/V) ammoniacal liquor regulate pH to neutral, the fermentation reaction time is 30 hours.
HA content can reach about 0.7-8.5 g/L after measured.Because of the synthetic aerobic of HA and than stable p H, for further improving the output of engineering bacteria, the present invention has carried out fermentor tank HA synthetic and has cultivated.
Embodiment 3
Hyaluronic fermentor cultivation is synthetic among the pHK/JM109:
Provoke 3-5 the single bacterium colony of the pHK/JM109 through line and incubated overnight from the LB flat board of Amp100ug/ml+Km100 ug/ml, place 100ml TB substratum (Terrific Broth): 12 g/L tryptones (Tryptone), 24 g/L yeast extracts (Yeast extract), 9.4 g/L K
2HPO
4With 2.2 g/L KH
2PO
4(pH6.8), incubated overnight.This culture is through centrifugal collection thalline, and thalline suspends with 20ml TB, all changes the fermentor tank (Bioreactor, BIOSTAT Bplus Sartoris BBI system Germany product) of 1L over to.Fermentation tank culture medium is that TB contains penbritin (Amp) 100ug/ml+ kantlex (Km) 100 ug/ml, and cumulative volume is 600ml.37 ℃ of controlled temperature, rotating speed 1200rpm feeds flow and is the mixed gas (oxygen: air 1:10 v/v) of 60ml/min, and regulates pH to 6.8 automatically with 28% ammoniacal liquor and 4 mol/L HCl.Cultivated about 4 hours, as culture OD
600Reach at 5 o'clock, adding IPTG makes its final concentration reach 1mM, simultaneously temperature of reaction is adjusted to 30 ℃ and cultivates 2 hours to induce the expression of pmHas and kfiD, add 50%(W/V this moment) glucose and 10%(W/V) ammonium phosphate (pH6.8) makes that glucose and ammonium phosphate content are respectively 50g/L and 1g/L in the fermented liquid, cultivate after 10 hours for 30 ℃, adding IPTG, glucose and ammonium phosphate once more makes its concentration be respectively 0.5mM, 50g/L and 1g/L, mixed solution is cultivated after 14 hours for 30 ℃, finish totally 30 hours fermentation reactions, obtain on average to be about 2-3 g/L HA.
Embodiment 4
Hyaluronic fermentor cultivation is synthetic among the pHK/JM109:
Provoke 3-5 the single bacterium colony of the pHK/JM109 through line and incubated overnight from the LB flat board of Amp50ug/ml+Km25 ug/ml, place 100ml TB substratum (Terrific Broth): 12 g/L tryptones (Tryptone), 24 g/L yeast extracts (Yeast extract), 9.4 g/L K
2HPO
4With 2.2 g/L KH
2PO
4(pH6.8), incubated overnight.This culture is through centrifugal collection thalline, and thalline suspends with 50ml TB, all changes the fermentor tank (Bioreactor, BIOSTAT Bplus Sartoris BBI system Germany product) of 5L over to.Fermentation tank culture medium is that TB contains penbritin (Amp) 50ug/ml+ kantlex (Km) 25 ug/ml, and cumulative volume is 3000ml.37 ℃ of controlled temperature, rotating speed 1200rpm feeds flow and is the mixed gas (oxygen: air 1:10 v/v) of 300ml/min, and regulates pH to 7.2 automatically with 28% ammoniacal liquor and 4 mol/L HCl.Cultivated about 4 hours, as culture OD
600Reach at 5 o'clock, add IPTG and make its final concentration reach 1mM, simultaneously temperature of reaction is adjusted to 33 ℃ and cultivates 2 hours to induce
PmHasWith
KfiDExpression, add 50%(W/V this moment) glucose and 10%(W/V) ammonium phosphate (pH6.8), make that glucose and ammonium phosphate content are respectively 50g/L and 1g/L in the fermented liquid, cultivate after 10 hours for 30 ℃, adding IPTG, glucose and ammonium phosphate once more makes its concentration be respectively 0.5mM, 50g/L and 1g/L, mixed solution is cultivated after 14 hours for 30 ℃, finishes totally 30 hours fermentation reactions, obtains on average to be about 2-3 g/L HA.
From Fig. 4 as seen, carry out the production of HA in fermentor tank, cell concn is greatly improved, OD
600Can reach 25-30, HA content obtains 2-2.5g/L, has put forward synthesis capability greatly, for condition has been prepared in large-scale production.
Hyaluronic extraction with separate:
The reaction mixture of above-mentioned fermentative production adds the dehydrated alcohol of 1/10 volume, 20% hexadecyl bromination ethamine (Cetyl Trimethyl Ammonium Bromide CTAB) and 2 times of volumes, places 10min behind the mixing.Got precipitation in centrifugal 10 minutes with 14000rpm.(too high because of hyaluronic acid contents sometimes, solution is divided into three layers of (see figure 3), and hyaluronic acid is difficult for precipitation, can suitably dilute initial reaction mixture in this case).Precipitation is used 1 times of volume once more, and the sodium-chlor of 1M suspends at 42 ℃ and extracted about 2 hours, the centrifugal collection supernatant liquor of 12000rpm, and after corresponding precipitation is used the resuspended 10min of the sodium-chlor of 1/10 volume 1M once more, resuspended mixing recentrifuge, supernatant solution abandons precipitation after merging.The supernatant solution that merges adds 2.5 times dehydrated alcohol, and mixing was placed 5 minutes, and centrifuging and taking precipitation, precipitation be with after 70% washing with alcohol, drying or heavily be dissolved in the 1M NaCl solution and be used for HA content and molecular weight determination.
The observation of thalli morphology behind the synthetic hyaluronic acid of pHK/JM109:
In HA synthetic reaction system, get about 2 μ l mixtures, place and allow liquid air-dry on the slide glass, air-dry bacterium is with 5 minutes (polychromatophilia reagent of 0.1% polychromatophilia reagent dyeing, Stains all is the Sigma product, http://www.sigmaaldrich.com) this dye liquor solvent (methane amide: Virahol, v/v7:3) preparation.The unnecessary fuel in dyeing back with distilled water flushing after, directly the micro-sight of 1000X is looked into and is collected pictures with CCD.See the metamorphosis of looking into the synthetic back of hyaluronic acid bacterial cell for further improving resolving power, the pHK/JM109 cell is directly observed with environmental scanning electronic microscope (ESEM) in the reaction system.Found that HA synthetic causes the coli somatic overstriking, terminal color depth, the sticking connection of thalline (Fig. 4).Control cells under ESEM (pBQ/JM109) smoother, HA synthetic cell (pHK/JM109) then surface irregularity (see figure 4) and thalline two ends have tangible material to pile up, and illustrate that cell has synthesized HA, and accumulate on the thalline surface.Color depth from the bacterium two ends that observe, infer that two ends may be the main site (see figure 1)s of the active secretion of thalline HA.
Hyaluronic enzymatic degradation is identified:
For further confirming that the said extracted thing is a hyaluronic acid really, utilize Sigma company from separate the hyaluronic acid streptomycete (
Streptomyces hyalurolyticus) middle purifying, the energy hyaluronic Unidasa of single-minded hydrolysis (Sigma product article No.: H 1136) is hydrolyzed, and carries out Analysis and Identification with the ion-exchange type HPLC of Dai An company (Dionex BioLC).With 250mU enzyme/mgHA ratio, 37 ℃ of hydrolysis totally 10 hours, being hydrolyzed respectively at sampling in 0,2.5,5 and 10 hour, the generation of hyaluronic acid 4 oligosaccharides detects in the mixture.The detailed process that ion-exchange type HPLC analyzes is, the enzymolysis biased sample is through 100 ℃, 5min termination reaction, mixture is centrifugal through 13000rpm, 0.2uM strainer filter after, the last Dionex BioLC (Sunnyvale of system, CA, the U.S.) analyze, this system separates with CarboPac PA20 post, electrochemical detector (Dionex ED50 electrochemical detector) carries out signal monitoring, the concrete ginseng of this detector is set to (waveform:t=0.41 sec, p=-2.00 V; T=0.42 sec, p=-2.00 V; T=0.43 sec, p=0.60 V; T=0.44 sec, p=-0.10 V; T=0.50 sec, p=-0.10 V). use the oligosaccharides of buying from Sigma company in the analytic process, Oligo-HA4, (production number: O9140-5MG) identify (appearance time of Dionex BioLC systems analysis is about 15min) for standard substance.Mobile of chromatography is A solution (the 200 mM NaOH that the degassing is handled, B solution (degassing is handled and contained 200 mM NaOH and 1M NaCl), flow velocity is 0.5 ml/min, A liquid and B liquid are all inflated with rare gas element helium in The whole analytical process, and separately proportionlity changes as follows in the gradient elution process: t=0 min, 5:95 (A liquid: B liquid, down together); T=5 min, 5:95; T=10 min, 20:80; T=20 min, 20:80; T=21 min, 100:0; T=30 min, 100:0; T=35 min, 5:95; T=50 min.As shown in Table 1, institute's extract mass-energy is by single-minded degraded hyaluronic acid, derive from separate the hyaluronic acid streptomycete (
Streptomyces hyalurolyticus) Unidasa degrade.Thereby conclusive evidence pmHas and kfiD efficiently express in intestinal bacteria, make the e. coli jm109 bacterial strain that can not synthesize HA under the natural condition change the synthetic bacterial strain of HA.
The mensuration of hyaluronic acid contents:
Conventional hyaluronic analytical procedure is with people such as Bitter (Bitter T et al, A modified uronic acid carbazole reaction .Anal. Biochem. 1,962 4,330 – 334.) carbazole (carbazole) analytical procedure.Hyaluronic content is by its hydrolysate in this method, glucuronic acid (glucuronic acid), content calculate.Learn from else's experience sample 1 mL of different dilutions of detailed process.In ice-water bath, add the 6 mL vitriol oils, after shaking up, be put in and keep 20 min in 85 ℃ of water-baths, take out to place then and be chilled to room temperature on ice, add 0.2 mL carbazole liquid (50 mg carbazoles are dissolved in 50 mL, 95% ethanol), after placing 100 ℃ of water-baths to keep 10 min, taking-up places and is chilled to room temperature on ice, measures the absorption of 530 nm. and typical curve is made of sigma company glucuronic acid standard model.Above-mentioned conventional determining method is proofreaied and correct by the immune analysis method of hyaluronic acid binding protein.Concrete hyaluronic acid radioimmunoassay kit (the Beijing North biotechnology research institute product that adopts, http://www.bnibt.com,) analyze, this assay kit adopts competition radio immunoassay, promptly HA in standard or the testing sample and 125I-HA common with the hyaluronic acid binding protein (HABP) of limiting the quantity of being at war with property association reaction under suitable condition.Part 125I-HA combines with HABP and forms mixture, and another part is unbound state.125I-HA and HABP bonded ratio depend on the content of non-marked HA in standard or the testing sample, and the content of non-marked HA is high more, and the mixture that 125I-HA and HABP form is few more.HA-HABP mixture and HABP antibody and second antibody form crosslinked polymer precipitation gets off, and measures sedimentary radiocounting.Can obtain typical curve and regression equation through after the data processing, find the HA content of sample from typical curve.After proofreading and correct, begin to carry out routine analysis with carbazole (carbazole) analytical procedure.Analytical results show that the shake flask fermentation hyaluronic acid concentration can reach 05g/L and in fermentor tank or the bio-reactor fermentation can make concentration reach 2.5g/L.
Hyaluronan molecule amount Determination of distribution:
For carrying out the mensuration of HA molecular weight distribution, above-mentioned hyaluronic extraction with separate, be dissolved in the 1M Hyaluronic acid sodium salt, add 1/10 volume 3M acetate and receive (pH5.5), equal-volume phenol: (after (1:1v/v) extracting once, water adds 2.5 times of ethanol sedimentation hyaluronic acids to chloroform, after throw out heavily is dissolved among 0.5M acetate and the 0.3 M Na2SO4, ((ASEC, aqueous size exclusion chromatography) method is measured the molecular weight of HA with the water gel exclusion chromatography.Concrete analysis is to carry out in island crystalline substance (Shimadzu) HPLC system; with Viscotek TSK Viscogel PWXL guard column; G3000, G4000 and G6000 connect altogether as analytical column, with RID-10A RI-detector (refractive Index detector) detection signal.The moving phase of chromatography consists of 0.5M acetate and 0.3 M Na2SO4, it is for want of known that flow velocity is controlled to be 0.6 mL/min. by island brilliant LC-20AD solvent transfer system, the hyaluronic acid standard molecule of different molecular weight, with buying from sigma company, (concrete Dextran is respectively a production number 31389 to the dextran of 40-2000kD, Mw~40,000 (Sigma), production number 31390 Mw~70,000 (Sigma), production number 09184, Mw~100,000 (Fluka) and production number 95771 Mw~2,000,000 (Sigma)) for after standard molecular weight comes the production standard curve, and with the known hyaluronic acid of molecular weight (Select-HA Hyaluronan 150K, mol wt 125-175 kDa, sigma production number S0201-1MG) proofread and correct after, estimate the hyaluronic molecular weight ranges that engineering colon bacillus of the present invention is produced.Analytical results shows that the hyaluronic acid molecular-weight average of engineering colon bacillus production of the present invention is between 130-150kD, but with respect to Sigma company hyaluronic acid, the about 4-4.5 of the hyaluronic molecular distribution scope of engineering colon bacillus synthetic of the present invention (Mw/Mn) sees Table 2 greater than Sigma standard transparent matter acid 2.9().
Remarks: the * commercialization is from HA sigma, Mw: polymeric molecular-weight average (weight average of polymer), Mn: polymeric mean number (number average of polymer), Mw/Mn: the molecular distribution scope of polymer.
More than show, in intestinal bacteria,, on express cell, accumulated HA and caused the change of surface structure by expressing hyaluronic acid synthetase pmHas and guanosine diphosphate(GDP) dehydrogenase gene kfiD; Engineering bacteria fermentation culture in common triangular flask can obtain about 1g/L HA content, with the fermentor cultivation of optimizing, put forward synthesis capability greatly, can obtain 2-2.5g/L HA content, produced the hyaluronic acid ability and obviously be better than the synthetic hyaluronic colibacillus engineering strain of report in the past.
Above-described efficient product hyaluronic acid engineering colon bacillus (pHK/JM109) prepares by the following method:
(1) make up the expression vector pQEpmHas contain hyaluronan synthase gene, with the pcr amplification method clone be derived from Pasteurella multocida (
Pasteurella multocidaSubsp.
Multocida) in hyaluronan synthase gene (
PAsteurella
mUltocida
hYaluronic
aCid synthase
PmHas), the design of its pcr amplification clone the primer is as follows:
Upstream primer pmHas P1 is 5'-TA
GGATCC ATGAACACATTATCACAAGCAAT-3', (SEQ ID No:3 in the sequence table) contains
BamH I site GGATCC and initiator codon ATG;
Downstream primer is
PmHasP2 is 5'-TA
GAGCTC TTASEQ ID No:4 in the TAGAGTTATACTATTAATAAT-3'(sequence table), contain
SacI site GAGCTC and terminator codon TAA;
The masterplate of PCR is the genomic dna of Pasteurella multocida strains A TCC 15742, the amplified production warp
BamH I and
SacBehind the I double digestion, connect into the identical restriction enzyme site among the commercial carrier pQE80L, insert fragment after DNA order-checking conclusive evidence does not have sudden change, with obtaining carrier called after pQEpmHas, gene is
PmHas(SEQ ID No:1 in the sequence table)
(2) make up the expression vector pQEkfiD contain the uridine diphosphoglucose dehydrogenase gene, with the pcr amplification method clone be derived from come from intestinal bacteria (
Escherichia coli, E.coli) bacterial strain k5(
E. coliK5) GDPG dehydrogenase gene (K in
5Capsule gene D,
KfiD), the design of primers of amplification is as follows:
Upstream primer
KfiD P1:5'-TGG
AGATCT ATGSEQ ID No:5 in the TTCGGAACACTAAAAATAACT G-3'(sequence table), contain Bgl II site AGATCT and initiator codon ATG);
Downstream primer
KfiD P2:5'-TT
CTCGAG TTASEQ ID No:6 in the GTCACATTTAAA CAAATCGCGAC-3'(sequence table), contain
XhoI site CTCGAG and terminator codon TAA;
The masterplate of PCR is the genomic dna of intestinal bacteria bacterium k5 strains A TCC 23500, the also product of purifying that successfully increases, warp
BglII and
XhoBehind the I double digestion, connect into the commercial carrier pQE80L's of Qiagen company
BamH I and
SalI site, gained carrier after DNA sequencing analysis conclusive evidence is inserted fragment and is not had sudden change, the carrier called after pQEkfiD that obtains, corresponding gene called after
KfiD gene (SEQ ID No:2 in the sequence table);
(3) make up co expression hyaluronan synthase gene and the recombinant vectors that contains the uridine diphosphoglucose dehydrogenase gene in the intestinal bacteria:
According to the DNA sequences Design PCR primer of the pQEkfiD carrier that builds, amplification T5 promoters driven
KfiThe fragment T5:kfiD that D expresses, concrete primer sequence design is as follows:
Upstream primer T5kfiD P1:5'-TA
GAGCTCCCTTTCGTCTTCAC
GSEQ ID No:7 in the TCGAGA-3'(sequence table), this primer contains
SacThe I site, GAGCTC, wherein subscript G represents C in the original pQE80L carrier is sported G, to eliminate it
XhoThe l site, CTCGAG;
Downstream primer T5kfiD P2:5'-TA
CTCGAGSEQ ID No:8 in the TTCTGAGGTCATTACTGGATCT-3'(sequence table), this primer contains
XhoI site, CTCGAG;
The masterplate of PCR pQEkfiD carrier, the T5:kfiD amplified production of purifying, at first connect into the pGEM-T-Vector(Promega product, www.promega.com) and transformed into escherichia coli JM109 bacterial strain, obtain intermediate carrier pT-T5KfiD, SEQ ID No:9 in the T5:kfiD(sequence table in this carrier) fragment, after sequencing analysis confirmed that nucleotide sequence does not have sudden change, this inserted T5:kfiD(fragment warp
SacI and
XhoBehind the I double digestion, connect into expression vector pQEpmHas's
SacI and
SalI site and obtaining
PmHasWith
KfiThe recombinant vectors pQHK of D gene coexpression in intestinal bacteria;
(4) structure of pHK
Dna sequence dna (GenBank No. Y14439) design primer according to the Gram-negative bacteria host wide spectrum plasmid pBBR122 of German MoBiTec company:
Upstream primer PBBR P1:5'-TTTGGT
GTCGACSEQ ID NO:10 in the CTTGCCAGCCCGTGGATATGTGG-3'(sequence table); Contain
SalThe I restriction enzyme site, GTCGAC
Downstream primer PBBR P1:5'-TTAGGT
GTCGACSEQ ID NO:11 in the TCTGTGATGGCTTCCATGTCGGCAG-3'(sequence table), contain
SalThe I restriction enzyme site, GTCGAC);
With comprising its replication site and kalamycin resistance gene among the above-mentioned primer amplification plasmid pBBR122 in interior fragment, the parameter of PCR amplification is: 95 ℃, 2 min, 1 circulation; 94 ℃, 30s, 55 ℃, 30s, 72 ℃, 3 min, 25 circulations; 72 ℃, 1 circulation of 10 min, the about 3.2 kb amplified productions of purifying are used
SalBehind the I enzymolysis, add ligase enzyme and connect certainly, self connect product transformed into escherichia coli JM109 bacterial strain by it, and obtain plasmid pRP (SEQ ID NO:12 in the sequence table) with kantlex screening, extract plasmid pRP, behind the SalI enzymolysis, connect into above-mentioned can be in intestinal bacteria coexpression pmHas and
KfiThe pQHK's of D gene
XhoThe I site, and obtain coexpression in Gram-negative bacteria
PmHasWith
KfiD synthesizes hyaluronic expression vector pHK;
(5) this recombinant vectors pHK is changed over to the hyaluronic engineering colon bacillus pHK/JM109(CGMCC of the described efficient product of acquisition NO:3926 in the e. coli jm109).
Above-described coli strain pHK/JM109 is the efficient hyaluronic acid engineering colon bacillus that produces, and wherein pHK is an expression vector, and its host strain is
E.coliJM109.
Dna sequence dna explanation involved in the present invention:
In the sequence table shown in the SEQ ID NO:1 be derived from Pasteurella multocida (
Pasteurella multocidaSubsp.
MultocidaIn hyaluronan synthase gene
PmHasThe coding region nucleotide sequence.
In the sequence table shown in the SEQ ID NO:2 is to be derived from intestinal bacteria k5 bacterial strain (middle GDPG dehydrogenase gene
KfiDThe coding region nucleotide sequence.
In the sequence table shown in the SEQ ID NO:3 be clone be derived from Pasteurella multocida (
Pasteurella multocidaSubsp.
Multocida) in hyaluronan synthase gene
PmHasThe base sequence of upstream primer.
In the sequence table shown in the SEQ ID NO:4 be clone be derived from Pasteurella multocida (
Pasteurella multocidaSubsp.
Multocida) in hyaluronan synthase gene
PmHasThe base sequence of downstream primer.
In the sequence table shown in the SEQ ID NO:5 is that the clone comes from GDPG dehydrogenase gene in the intestinal bacteria k5 bacterial strain
KfiThe base sequence of the upstream primer of D.
In the sequence table shown in the SEQ ID NO:6 is that the clone comes from GDPG dehydrogenase gene in the intestinal bacteria k5 bacterial strain
KfiThe base sequence of the downstream primer of D.
In the sequence table shown in the SEQ ID NO:7 is the base sequence of the segmental upstream primer of clone T5:kfiD.
In the sequence table shown in the SEQ ID NO:8 is the base sequence of the segmental downstream primer of clone T5:kfiD.
In the sequence table shown in the SEQ ID NO:9 is the segmental nucleotide sequence of T5:kfiD.
In the sequence table shown in the SEQ ID NO:10 is clone's PBRR122 kalamycin resistance gene and the base sequence that duplicates essential segmental upstream primer.
In the sequence table shown in the SEQ ID NO:11 is clone's PBRR122 kalamycin resistance gene and the base sequence that duplicates essential segmental downstream primer.
In the sequence table shown in the SEQ ID NO:12 is the nucleotide sequence of plasmid pRP.
The genetic resources that the present invention relates to:
1: kill Bath DS strains A TCC15742(Pasteurella multocida subsp. multocida (Lehmann and Neumann) Rosenbusch and Merchant) more; Genetic resources is taken from: U.S.'s typical case's culture is preserved center (ATCC); Obtain manner: buy price 225 U.S. dollars; Acquisition time: in January, 2008; Primary source: U.S. scientist KL Heddleston separates acquisition time from the turkey heart: in April, 1962
2: intestinal bacteria K5 strains A TCC23500(
Escherichia coli(Migula) Castellani and Chalmers, serotype O2a, 2b:K5 (L): H4; Genetic resources is taken from: U.S.'s typical case's culture is preserved center (ATCC) obtain manner: buy, price 225 U.S. dollars, acquisition time: in September, 2008 primary source: the Center for Disease Control (CDC) scientist Kauffmann separates from people urine, and acquisition time: July nineteen forty-three.
Sequence table
SEQUENCE LISTING
<110〉Yunnan Province's microbial fermentation engineering research centre company limited
<120〉efficiently produce the hyaluronic acid engineering colon bacillus
<130> /
<160> 12
<170> PatentIn version 3.3
<210> 1
<211> 2919
<212> DNA
<213> Pasteurella multocida subsp. Multocida(ATCC15742)
<400> 1
atgaatacat tatcacaagc aataaaagca tataacagca atgactatca attagcactc 60
aaattatttg aaaagtcggc ggaaatctat ggacggaaaa ttgttgaatt tcaaattacc 120
aaatgcaaag aaaaactctc agcacatcct tctgttaatt cagcacatct ttctgtaaat 180
aaagaagaaa aagtcaatgt ttgcgatagt ccgttagata ttgcaacaca actgttactt 240
tccaacgtaa aaaaattagt actttctgac tcggaaaaaa acacgttaaa aaataaatgg 300
aaattgctca ctgagaagaa atctgaaaat gcggaggtaa gagcggtcgc ccttgtacca 360
aaagattttc ccaaagatct ggttttagcg cctttacctg atcatgttaa tgattttaca 420
tggtacaaaa agcgaaagaa aagacttggc ataaaacctg aacatcaaca tgttggtctt 480
tctattatcg ttacaacatt caatcgacca gcaattttat cgattacatt agcctgttta 540
gtaaaccaaa aaacacatta cccgtttgaa gttatcgtga cagatgatgg tagtcaggaa 600
gatctatcac cgatcattcg ccaatatgaa aataaattgg atattcgcta cgtcagacaa 660
aaagataacg gttttcaagc cagtgccgct cggaatatgg gattacgctt agcaaaatat 720
gactttattg gcttactcga ctgtgatatg gcgccaaatc cattatgggt tcattcttat 780
gttgcagagc tattagaaga tgatgattta acaatcattg gtccaagaaa atacatcgat 840
acacaacata ttgacccaaa agacttctta aataacgcga gtttgcttga atcattacca 900
gaagtgaaaa ccaataatag tgttgccgca aaaggggaag gaacagtttc tctggattgg 960
cgcttagaac aattcgaaaa aacagaaaat ctccgcttat ccgattcgcc tttccgtttt 1020
tttgcggcgg gtaatgttgc tttcgctaaa aaatggctaa ataaatccgg tttctttgat 1080
gaggaattta atcactgggg tggagaagat gtggaatttg gatatcgctt attccgttac 1140
ggtagtttct ttaaaactat tgatggcatt atggcctacc atcaagagcc accaggtaaa 1200
gaaaatgaaa ccgatcgtga agcgggaaaa aatattacgc tcgatattat gagagaaaag 1260
gtcccttata tctatagaaa acttttacca atagaagatt cgcatatcaa tagagtacct 1320
ttagtttcaa tttatatccc agcttataac tgtgcaaact atattcaacg ttgcgtagat 1380
agtgcactga atcagactgt tgttgatctc gaggtttgta tttgtaacga tggttcaaca 1440
gataatacct tagaagtgat caataagctt tatggtaata atcctagggt acgcatcatg 1500
tctaaaccaa atggcggaat agcctcagca tcaaatgcag ccgtttcttt tgctaaaggt 1560
tattacattg ggcagttaga ttcagatgat tatcttgagc ctgatgcagt tgaactgtgt 1620
ttaaaagaat ttttaaaaga taaaacgcta gcttgtgttt ataccactaa tagaaacgtc 1680
aatccggatg gtagcttaat cgctaatggt tacaattggc cagaattttc acgagaaaaa 1740
ctcacaacgg ctatgattgc tcaccacttt agaatgttca cgattagagc ttggcattta 1800
actgatggat tcaatgaaaa aattgaaaat gccgtagact atgacatgtt cctcaaactc 1860
agtgaagttg gaaaatttaa acatcttaat aaaatctgct ataaccgtgt attacatggt 1920
gataacacat caattaagaa acttggcatt caaaagaaaa accattttgt tgtagtcaat 1980
cagtcattaa atagacaagg cataacttat tataattatg acgaatttga tgatttagat 2040
gaaagtagaa agtatatttt caataaaacc gctgaatatc aagaagagat tgatatctta 2100
aaagatatta aaatcatcca gaataaagat gccaaaatcg cagtcagtat tttttatccc 2160
aatacattaa acggcttagt gaaaaaacta aacaatatta ttgaatataa taaaaatata 2220
ttcgttattg ttctacatgt tgataagaat catcttacac cagatatcaa aaaagaaata 2280
ctagccttct atcataaaca tcaagtgaat attttactaa ataatgatat ctcatattac 2340
acgagtaata gattaataaa aactgaggcg catttaagta atattaataa attaagtcag 2400
ttaaatctaa attgtgaata catcattttt gataatcatg acagcctatt cgttaaaaat 2460
gacagctatg cttatatgaa aaaatatgat gtcggcatga atttctcagc attaacacat 2520
gattggatcg agaaaatcaa tgcgcatcca ccatttaaaa agctcattaa aacttatttt 2580
aatgacaatg acttaaaaag tatgaatgtg aaaggggcat cacaaggtat gtttatgacg 2640
tatgcgctag cgcatgagct tctgacgatt attaaagaag tcatcacatc ttgccagtca 2700
attgatagtg tgccagaata taacactgag gatatttggt tccaatttgc acttttaatc 2760
ttagaaaaga aaaccggcca tgtatttaat aaaacatcga ccctgactta tatgccttgg 2820
gaacgaaaat tacaatggac aaatgaacaa attgaaagtg caaaaagagg agaaaatata 2880
cctgttaaca agttcattat taatagtata actctataa 2919
<210> 2
<211> 1179
<212> DNA
<213> Escherichia coli K5(ATCC23500)
<400> 2
atgttcggaa cactaaaaat aactgtttca ggcgctggtt acgttgggct ttcaaatgga 60
attctaatgg ctcaaaatca tgaagtggtt gcatttgata cccatcaaaa aaaagttgac 120
ttacttaatg ataaactctc tcctatagag gataaggaaa ttgaaaatta tctttcaact 180
aaaatactta attttcgcgc aactactaac aaatatgaag cctataaaaa tgccaattac 240
gttattattg ctacaccaac gaattatgac ccaggttcaa attactttga tacatcaagc 300
gttgaagctg tcattcgtga cgtaacggaa atcaacccaa acgcaattat ggtggttaaa 360
tctacggtcc cagtaggttt cacaaaaaca attaaagaac atttaggtat taataatatt 420
atcttctctc cagaattttt acgagaagga agagccctat acgataatct ccatccatct 480
cgcattatta tcggtgaatg ttctgaacgg gcagaacgtt tggcagtgtt atttcaggaa 540
ggagcgatta aacaaaatat acccgtttta tttacagatt ctacggaagc ggaagcgatt 600
aagttatttt caaatactta tttggctatg cgagttgcat tttttaatga attggatagt 660
tacgcagaaa gttttggtct gaatacgcgt cagattattg acggtgtttg tttggatccg 720
cgcattggta attactacaa taatccttct tttggttatg gtggctactg tttgccaaaa 780
gataccaagc aattattagc caactatcag tctgttccga ataaacttat atctgcaatt 840
gttgatgcta accgtacacg taaggacttt atcactaatg ttattttgaa acatagacca 900
caagttgtgg gggtttatcg tttgattatg aaaagtggtt cagataattt tagagattct 960
tctattcttg gtattataaa gcgtatcaag aaaaaaggcg tgaaagtaat tatttatgag 1020
ccgcttattt ctggagatac attctttaac tcacctttgg aacgggagct ggcgatcttt 1080
aaagggaaag ctgatattat tatcactaac cgaatgtcag aggagttgaa cgatgtggtc 1140
gacaaagtct atagtcgcga tttgtttaaa tgtgactaa 1179
<210> 3
<211> 31
<212> DNA
<213〉artificial-synthetic DNA
<400> 3
taggatccat gaacacatta tcacaagcaa t 31
<210> 4
<211> 32
<212> DNA
<213〉artificial-synthetic DNA
<400> 4
tagagctctt atagagttat actattaata at 32
<210> 5
<211> 34
<212> DNA
<213〉artificial-synthetic DNA
<400> 5
tggagatcta tgttcggaac actaaaaata actg 34
<210> 6
<211> 34
<212> DNA
<213〉artificial-synthetic DNA
<400> 6
ttctcgagtt agtcacattt aaacaaatcg cgac 34
<210> 7
<211> 29
<212> DNA
<213〉artificial-synthetic DNA
<400> 7
tagagctccc tttcgtcttc acgtcgaga 29
<210> 8
<211> 30
<212> DNA
<213〉artificial-synthetic DNA
<400> 8
tactcgagtt ctgaggtcat tactggatct 30
<210> 9
<211> 1423
<212> DNA
<213〉engineering makes up fragment
<400> 9
tagagctccc tttcgtcttc acgtcgagaa atcataaaaa atttatttgc tttgtgagcg 60
gataacaatt ataatagatt caattgtgag cggataacaa tttcacacag aattcattaa 120
agaggagaaa ttaactatga gaggatcgca tcaccatcac catcacggat ctatgttcgg 180
aacactaaaa ataactgttt caggcgctgg ttacgttggg ctttcaaatg gaattctaat 240
ggctcaaaat catgaagtgg ttgcatttga tacccatcaa aaaaaagttg acttacttaa 300
tgataaactc tctcctatag aggataagga aattgaaaat tatctttcaa ctaaaatact 360
taattttcgc gcaactacta acaaatatga agcctataaa aatgccaatt acgttattat 420
tgctacacca acgaattatg acccaggttc aaattacttt gatacatcaa gcgttgaagc 480
tgtcattcgt gacgtaacgg aaatcaaccc aaacgcaatt atggtggtta aatctacggt 540
cccagtaggt ttcacaaaaa caattaaaga acatttaggt attaataata ttatcttctc 600
tccagaattt ttacgagaag gaagagccct atacgataat ctccatccat ctcgcattat 660
tatcggtgaa tgttctgaac gggcagaacg tttggcagtg ttatttcagg aaggagcgat 720
taaacaaaat atacccgttt tatttacaga ttctacggaa gcggaagcga ttaagttatt 780
ttcaaatact tatttggcta tgcgagttgc attttttaat gaattggata gttacgcaga 840
aagttttggt ctgaatacgc gtcagattat tgacggtgtt tgtttggatc cgcgcattgg 900
taattactac aataatcctt cttttggtta tggtggctac tgtttgccaa aagataccaa 960
gcaattatta gccaactatc agtctgttcc gaataaactt atatctgcaa ttgttgatgc 1020
taaccgtaca cgtaaggact ttatcactaa tgttattttg aaacatagac cacaagttgt 1080
gggggtttat cgtttgatta tgaaaagtgg ttcagataat tttagagatt cttctattct 1140
tggtattata aagcgtatca agaaaaaagg cgtgaaagta attatttatg agccgcttat 1200
ttctggagat acattcttta actcaccttt ggaacgggag ctggcgatct ttaaagggaa 1260
agctgatatt attatcacta accgaatgtc agaggagttg aacgatgtgg tcgacaaagt 1320
ctatagtcgc gatttgttta aatgtgacta actcgaccca agcttaatta gctgagcttg 1380
gactcctgtt gatagatcca gtaatgacct cagaactcga gta 1423
<210> 10
<211> 33
<212> DNA
<213〉artificial-synthetic DNA
<400> 10
tggtgtcgac cttgccagcc cgtggatatg tgg 33
<210> 11
<211> 35
<212> DNA
<213〉artificial-synthetic DNA
<400> 11
aggtgtcgac tctgtgatgg cttccatgtc ggcag 35
<210> 12
<211> 3266
<212> DNA
<213> pBBR122
<400> 12
gtcgaccttg ccagcccgtg gatatgtgga cgatggccgc gagcggccac cggctggctc 60
gcttcgctcg gcccgtggac aaccctgctg gacaagctga tggacaggct gcgcctgccc 120
acgagcttga ccacagggat tgcccaccgg ctacccagcc ttcgaccaca tacccaccgg 180
ctccaactgc gcggcctgcg gccttgcccc atcaattttt ttaattttct ctggggaaaa 240
gcctccggcc tgcggcctgc gcgcttcgct tgccggttgg acaccaagtg gaaggcgggt 300
caaggctcgc gcagcgaccg cgcagcggct tggccttgac gcgcctggaa cgacccaagc 360
ctatgcgagt gggggcagtc gaaggcgaag cccgcccgcc tgccccccga gacctgcagg 420
gggggggggg cgctgaggtc tgcctcgtga agaaggtgtt gctgactcat accaggcctg 480
aatcgcccca tcatccagcc agaaagtgag ggagccacgg ttgatgagag ctttgttgta 540
ggtggaccag ttggtgattt tgaacttttg ctttgccacg gaacggtctg cgttgtcggg 600
aagatgcgtg atctgatcct tcaactcagc aaaagttcga tttattcaac aaagccgccg 660
tcccgtcaag tcagcgtaat gctctgccag tgttacaacc aattaaccaa ttctgattag 720
aaaaactcat cgagcatcaa atgaaactgc aatttattca tatcaggatt atcaatacca 780
tatttttgaa aaagccgttt ctgtaatgaa ggagaaaact caccgaggca gttccatagg 840
atggcaagat cctggtatcg gtctgcgatt ccgactcgtc caacatcaat acaacctatt 900
aatttcccct cgtcaaaaat aaggttatca agtgagaaat caccatgagt gacgactgaa 960
tccggtgaga atggcaaaag cttatgcatt tctttccaga cttgttcaac aggccagcca 1020
ttacgctcgt catcaaaatc actcgcatca accaaaccgt tattcattcg tgattgcgcc 1080
tgagcgagac gaaatacgcg atcgctgtta aaaggacaat tacaaacagg aatcgaatgc 1140
aaccggcgca ggaacactgc cagcgcatca acaatatttt cacctgaatc aggatattct 1200
tctaatacct ggaatgctgt tttcccgggg atcgcagtgg tgagtaacca tgcatcatca 1260
ggagtacgga taaaatgctt gatggtcgga agaggcataa attccgtcag ccagtttagt 1320
ctgaccatct catctgtaac atcattggca acgctacctt tgccatgttt cagaaacaac 1380
tctggcgcat cgggcttccc atacaatcga tagattgtcg cacctgattg cccgacatta 1440
tcgcgagccc atttataccc atataaatca gcatccatgt tggaatttaa tcgcggcctc 1500
gagcaagacg tttcccgttg aatatggctc ataacacccc ttgtattact gtttatgtaa 1560
gcagacagtt ttattgttca tgatgatata tttttatctt gtgcaatgta acatcagaga 1620
ttttgagaca caacgtggct ttcccccccc cccctgcagg tcccgagcct cacggcggcg 1680
agtgcggggg ttccaagggg gcagcgccac cttgggcaag gccgaaggcc gcgcagtcga 1740
tcaacaagcc ccggaggggc cactttttgc cggaggggga gccgcgccga aggcgtgggg 1800
gaaccccgca ggggtgccct tctttgggca ccaaagaact agatataggg cgaaatgcga 1860
aagacttaaa aatcaacaac ttaaaaaagg ggggtacgca acagctcatt gcggcacccc 1920
ccgcaatagc tcattgcgta ggttaaagaa aatctgtaat tgactgccac ttttacgcaa 1980
cgcataattg ttgtcgcgct gccgaaaagt tgcagctgat tgcgcatggt gccgcaaccg 2040
tgcggcaccc taccgcatgg agataagcat ggccacgcag tccagagaaa tcggcattca 2100
agccaagaac aagcccggtc actgggtgca aacggaacgc aaagcgcatg aggcgtgggc 2160
cgggcttatt gcgaggaaac ccacggcggc aatgctgctg catcacctcg tggcgcagat 2220
gggccaccag aacgccgtgg tggtcagcca gaagacactt tccaagctca tcggacgttc 2280
tttgcggacg gtccaatacg cagtcaagga cttggtggcc gagcgctgga tctccgtcgt 2340
gaagctcaac ggccccggca ccgtgtcggc ctacgtggtc aatgaccgcg tggcgtgggg 2400
ccagccccgc gaccagttgc gcctgtcggt gttcagtgcc gccgtggtgg ttgatcacga 2460
cgaccaggac gaatcgctgt tggggcatgg cgacctgcgc cgcatcccga ccctgtatcc 2520
gggcgagcag caactaccga ccggccccgg cgaggagccg cccagccagc ccggcattcc 2580
gggcatggaa ccagacctgc cagccttgac cgaaacggag gaatgggaac ggcgcgggca 2640
gcagcgcctg ccgatgcccg atgagccgtg ttttctggac gatggcgagc cgttggagcc 2700
gccgacacgg gtcacgctgc cgcgccggta gcacttgggt tgcgcagcaa cccgtaagtg 2760
cgctgttcca gactatcggc tgtagccgcc tcgccgccct ataccttgtc tgcctccccg 2820
cgttgcgtcg cggtgcatgg agccgggcca cctcgacctg aatggaagcc ggcggcacct 2880
cgctaacgga ttcaccgttt ttatcaggct ctgggaggca gaataaatga tcatatcgtc 2940
aattattacc tccacgggga gagcctgagc aaactggcct caggcatttg agaagcacac 3000
ggtcacactg cttccggtag tcaataaacc ggtaaaccag caatagacat aagcggctat 3060
ttaacgaccc tgccctgaac cgacgaccgg gtcgaatttg ctttcgaatt tctgccattc 3120
atccgcttat tatacttatt caggcgtagc accaggcgtt taagggcacc aataactgcc 3180
ttaaaaaaat tacgccccgc cctgccactc atcgcagtac tgttgtaatt cattaagcat 3240
tctgccgaca tggaagccat cacaga 3266
Claims (2)
1. hyaluronic preparation method is characterized in that producing with engineering colon bacillus pHK/JM109 that hyaluronic shake-flask culture is synthetic to be undertaken by following: in the 500ml-2500ml triangular flask, contain 25-50 mM K with cumulative volume 100ml-500ml
2HPO
43H
2O, pH6.5-7.2,2-4mM g/L MgSO47H2O, 20-40 mM/L citric acid, 1-2 mM MnCl
2, 300-400 mM glucose 50-75 mM nitrogen acetylglucosamine adds in the system of 5-10 mM lactose, 10-30 g/L glycerine, 3-5g/L caseinic acid hydrolyzate (Casamino acid) and expresses
PmHasWith
KfiThe pHK/JM109 of D makes somatic cells concentration reach 4-5% W/V, and fermentation condition is 30-33 ℃, 250 rpm, and it is extremely neutral to regulate pH with the ammoniacal liquor of 28% V/V, the fermentation reaction time is 30-36 hour.
2. hyaluronic preparation method, it is characterized in that producing that hyaluronic fermentor cultivation is synthetic is undertaken by following: provoke 3-5 through the single bacterium colony of the pHK/JM109 of line and incubated overnight from the LB flat board of Amp50-100ug/ml+Km25-100ug/ml with engineering colon bacillus pHK/JM109, place 100ml TB substratum (Terrific Broth), incubated overnight; This culture is through centrifugal collection thalline, thalline suspends with 20-50ml TB, all changes the fermentor tank of 1-5L over to, and fermentation tank culture medium is the TB substratum and contains Amp50-100 ug/ml+Kmn25-100 ug/ml, cumulative volume is 600-3000 ml, 37 ℃ of controlled temperature, rotating speed 1200 rpm, feeding flow is the mixed gas of 60 ml/min, be oxygen: air 1:10 v/v, and, cultivated 4 hours, as culture OD with 28% V/V ammoniacal liquor and 4 mol/L HCl adjusting pH to 6.8-7.2
600Reach at 5 o'clock, adding IPTG makes its final concentration reach 0.5-1 mM, simultaneously temperature of reaction being adjusted to 30-33 ℃ cultivated 2 hours, add 50% W/V glucose and 10% W/V ammonium phosphate pH6.8 this moment, make that glucose and ammonium phosphate content are respectively 50 g/L and 1 g/L in the fermented liquid, cultivate after 10 hours for 30 ℃, adding IPTG, glucose and ammonium phosphate once more makes its concentration be respectively 0.5 mM, 50 g/L and 1 g/L, mixed solution is cultivated after 14-30 hour for 30 ℃ and is finished fermentation, obtains the hyaluronic acid of 2-3 g/L concentration.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110006226 CN102154405B (en) | 2011-01-13 | 2011-01-13 | Preparation method of hyaluronic acid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110006226 CN102154405B (en) | 2011-01-13 | 2011-01-13 | Preparation method of hyaluronic acid |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102154405A true CN102154405A (en) | 2011-08-17 |
CN102154405B CN102154405B (en) | 2013-03-20 |
Family
ID=44436076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110006226 Active CN102154405B (en) | 2011-01-13 | 2011-01-13 | Preparation method of hyaluronic acid |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102154405B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105861596A (en) * | 2015-01-23 | 2016-08-17 | 中国科学院微生物研究所 | Method for preparing hyaluronic acid |
CN106381279A (en) * | 2016-08-29 | 2017-02-08 | 中国药科大学 | Extracellular polymeric substances, preparation method and application thereof |
CN110045045A (en) * | 2019-05-28 | 2019-07-23 | 中山市天然保贸易有限公司 | The detection method of hyaluronic acid contents in a kind of facial mask |
CN112522125A (en) * | 2020-12-28 | 2021-03-19 | 河北省微生物研究所 | Hyaluronidase engineering bacterium and construction method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101633931A (en) * | 2008-07-25 | 2010-01-27 | 山东省生物药物研究院 | Hyaluronidase expression vector and application thereof |
CN101643760A (en) * | 2009-09-04 | 2010-02-10 | 四川理工学院 | Method for increasing the yield of hyaluronic acid |
-
2011
- 2011-01-13 CN CN 201110006226 patent/CN102154405B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101633931A (en) * | 2008-07-25 | 2010-01-27 | 山东省生物药物研究院 | Hyaluronidase expression vector and application thereof |
CN101643760A (en) * | 2009-09-04 | 2010-02-10 | 四川理工学院 | Method for increasing the yield of hyaluronic acid |
Non-Patent Citations (4)
Title |
---|
HUIMIN YU等: "A High-Throughput Screen for Hyaluronic Acid Accumulation in Recombinant Escherichia coli Transformed by Libraries of Engineered Sigma Factors", 《BIOTECHNOLOGY AND BIOENGINEERING》, vol. 101, no. 4, 1 November 2008 (2008-11-01) * |
HUIMIN YU等: "Metabolic engineering of Escherichia coli for biosynthesis of hyaluronic acid", 《METABOLIC ENGINEERING》, vol. 10, 31 December 2008 (2008-12-31) * |
刘飞等: "兽疫链球菌透明质酸酶在大肠杆菌中的高效表达和酶学性质", 《山东生物化学与分子生物学会2009年学术会议论文汇编》, 31 December 2009 (2009-12-31) * |
易梅等: "透明质酸的应用及制备方法", 《中国生物工程杂志》, vol. 28, no. 6, 31 December 2008 (2008-12-31) * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105861596A (en) * | 2015-01-23 | 2016-08-17 | 中国科学院微生物研究所 | Method for preparing hyaluronic acid |
CN105861596B (en) * | 2015-01-23 | 2020-02-04 | 中国科学院微生物研究所 | Preparation method of hyaluronic acid |
CN106381279A (en) * | 2016-08-29 | 2017-02-08 | 中国药科大学 | Extracellular polymeric substances, preparation method and application thereof |
CN106381279B (en) * | 2016-08-29 | 2019-11-05 | 中国药科大学 | A kind of extracellular polysaccharide of bacteria, preparation method and its application |
CN110045045A (en) * | 2019-05-28 | 2019-07-23 | 中山市天然保贸易有限公司 | The detection method of hyaluronic acid contents in a kind of facial mask |
CN110045045B (en) * | 2019-05-28 | 2021-08-06 | 中山市天然保贸易有限公司 | Method for detecting content of hyaluronic acid in facial mask |
CN112522125A (en) * | 2020-12-28 | 2021-03-19 | 河北省微生物研究所 | Hyaluronidase engineering bacterium and construction method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN102154405B (en) | 2013-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105055440B (en) | Purposes of oligomerization hyaluronic acid or oligomerization hyaluronate and combinations thereof | |
ES2396955T3 (en) | Procedure for the purification of high molecular weight hyaluronic acid | |
CN1322121C (en) | Hyaluronan synthase gene and uses thereof | |
Coste et al. | Production of sulfated oligosaccharides from the seaweed Ulva sp. using a new ulvan-degrading enzymatic bacterial crude extract | |
CN101608166B (en) | Flavobacterium strain and application thereof in generating agarase | |
CN105431534A (en) | beta-1,3-glucanase, polynucleotide, recombinant vector, transformant, production method for beta-1,3-glucanase, enzyme preparation, and production method for paramylon having reduced molecular weight | |
CN102154405B (en) | Preparation method of hyaluronic acid | |
da Silva et al. | Xanthan: biotechnological production and applications | |
CN102112617A (en) | Process for co-production of chitin, its derivatives and polymers containing glucose, mannose and/or galactose, by fermentation of yeast pichia pastoris | |
CN110923173A (en) | Enterobacter and application thereof | |
CN102154190B (en) | Engineering escherichia coli capable of efficiently producing hyaluronic acid and preparation method thereof | |
CN108410783B (en) | Method for producing glucosamine by culturing escherichia coli and fermenting | |
CN109988731A (en) | One plant of welan gum superior strain Sphingol single-cell TJA 3-1 and its methods and applications for producing welan gum | |
CN106367459A (en) | Method for preparing oligomeric hyaluronic acid with different molecular weights | |
CN106434475B (en) | One streptomycete category polysaccharide degradation bacteria and its cultural method and application | |
Wang et al. | Structural characterization and bioactivity of exopolysaccharide synthesized by Geobacillus sp. TS3-9 isolated from radioactive radon hot spring | |
JP5969390B2 (en) | Fucose-containing bacterial biopolymer | |
US20080064073A1 (en) | Process for Preparing | |
CN102154360B (en) | Recombinant expression vectors pQHK and pHK producing hyaluronic acid and construction method thereof | |
CN112458022B (en) | Bacillus licheniformis Bl22 for high yield of chitin deacetylase and related products and application thereof | |
CN104498412B (en) | Cohnella sp. capable of degrading agar | |
CN105567606A (en) | Arthrobacter globiformis and hyaluronidase generated by arthrobacter globiformis | |
CN101113436B (en) | Hyaluronan synthase gene and uses thereof | |
CN113322207B (en) | Microbacterium XL1 and application thereof in Levan fructan production | |
Kazak | Exopolysaccharide production by Halomonas strains isolated from Turkey |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method of hyaluronic acid Effective date of registration: 20231120 Granted publication date: 20130320 Pledgee: Kunming Dongfeng Sub branch of Bank of China Ltd. Pledgor: MICROBIAL FERMENTATION ENGINEERING RESEARCH CENTER Co.,Ltd. OF YUNNAN PROVINCE Registration number: Y2023530000066 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |